UNSPSC 51392230: Tramazoline hydrochloride monohydrate

This classification denotes an alpha-adrenergic agonist with the molecular formula C13H17N3.ClH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9DF5N42U1U, chemically known as n-(5,6,7,8-tetrahydronaphthalen-1-yl)-4,5-dihydro-1h-imidazol-2-amine hydrochloride monohydrate, but more generally known as tramazoline hydrochloride monohydrate, which bears US NIH Compound Identifier 19472.

European Medicines Agency schedules tramazoline hydrochloride monohydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11211MIG. Most nations, for tariff purposes, schedule tramazoline hydrochloride monohydrate under HS 29332990. SMILES: C1CC2C(C(C1)NC3=NCCN3)CCCC2.O.CL.

UNSPSC 51392230 Tramazoline hydrochloride monohydrate is a Commodity code that represents pharmaceutical active ingredients and finished pharmaceutical products for state and local health and human services procurement. Recent state and local activity under this code shows acquisition of naloxone and related emergency pharmaceutical products, along with exploratory procurement for direct-to-manufacturer prescription programs. Health departments and human services commissions are the primary issuing bodies, soliciting these materials to support community health initiatives, emergency response capabilities, and pharmacy benefit management modernization. The scope of work centers on the procurement and delivery of pharmaceutical supplies and management systems that serve public health functions, including opioid overdose response and drug deactivation infrastructure.

Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, with a response deadline of July 26, 2023. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, soliciting vendor information on direct-to-manufacturer prescription programs and pharmacy benefit management models, representing preliminary market research before formal competitive solicitation. Geographic activity centers on Florida and Texas, with recent procurement driven by community health initiatives and state-level pharmacy benefit modernization efforts. The code shows limited but concrete recent activity, with opportunities emerging from health departments and human services agencies rather than other local government issuing bodies.